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Abstract
We studied 2332 individuals with monoallelic mutations in MUTYH among 9504 relatives of 264
colorectal cancer (CRC) cases with a MUTYH mutation. We estimated CRC risks, through 70 y of
age, of 7.2% for male carriers of monoallelic mutations (95% confidence interval [CI], 4.6%–
11.3%) and 5.6% for female carriers of monoallelic mutations (95% CI, 3.6%–8.8%), irrespective
of family history. For monoallelic MUTYH mutation carriers with a first-degree relative with
CRC, diagnosed by 50 y of age who does not have the MUTYH mutation, risks of CRC were
12.5% for men and (95% CI, 8.6%–17.7%) and 10% for women (95% CI, 6.7%–14.4%). Risks of
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CRC for carriers of monoallelic mutations in MUTYH with a first-degree relative with CRC are
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sufficiently high to warrant more intensive screening than for the general population.
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MUTYH is a base excision repair gene that detects and protects against oxidative DNA
damage.1 Individuals with germline mutations in both alleles (biallelic mutation carriers),
whether they are homozygotes or compound heterozygotes, develop MUTYH-associated
polyposis, an autosomal recessive disorder with substantially increased risk of CRC.2
Individuals with germline mutations in one allele (monoallelic mutation carriers) have a
small increased risk of CRC3–5. Due to the rarity of these mutations,4, 6 previous studies
have had limited ability to provide precise estimates of age- and sex-specific CRC risks for
MUTYH mutation carriers. Further, the variability in CRC risk between carriers has not been
quantified. Modelling of this variability can indicate a potential role for modifiers of risk.
RESULTS
We identified 9504 relatives (4613 females) from the families of the 264 (236 population-
based and 28 clinic-based) probands with a monoallelic or biallelic MUTYH mutation from
the Colon Cancer Family Registry; 138 (52%) from USA, 81 (31%) from Canada, and 45
(17%) from Australia and New Zealand. In the relatives, we observed 261 CRCs (114
females) whose ages at diagnosis had a median of 65 (range 26–98) years. MUTYH mutation
status was known for 340 relatives (13 biallelic mutation carriers, 142 monoallelic mutation
carriers, and 185 non-carriers). We estimated an additional 43 biallelic and 2190 monoallelic
mutation carriers among non-genotyped relatives, giving a total estimated number of 56
biallelic and 2332 monoallelic mutation-carrying relatives in our sample.
Our methods allowed for CRC risk estimation in mutation families to be due to the MUTYH
mutation as well as polygenic factors (combination of a large number of CRC-associated
genetic susceptibility loci).7 We estimated CRC risks, through 70y of age, for male and
female to be: 75.4% (95%CI, 41.2%–96.6%) and 71.7% (95%CI, 44.5%–92.1%),
respectively, for biallelic mutation carriers, and 7.2% (95%CI, 4.6%– 11.3%) and 5.6%
(95%CI, 3.6%–8.8%), respectively, for monoallelic mutation carriers (Figure 1). The
estimated CRC risks, through 70y of age, for monoallelic mutation carriers with a first-
degree relative with CRC were similar whether the relative was untested or a non-carrier or
a monoallelic mutation carrier: approximately 12% (95%CI, 9%–18%) and 10% (95%CI,
7%–14%) respectively for males and females in comparison with males and females from
the general population (2.9% and 2.1% respectively). However, if their affected first-degree
relative was a biallelic mutation carrier then risks of CRC, through 70y of age, for
monoallelic mutation carriers was estimated to be 10.4% (95%CI, 7.0%–15.0%) and 8.2%
(95%CI, 5.4%–12.0%) respectively for males and females (Table 1). In addition, we
estimated CRC risks for six other scenarios (Supplementary Figure 1). The highest risk of
CRC for a monoallelic mutation carrier corresponded to having two affected first-degree
relatives: one is a biallelic mutation carrier and one is a noncarrier (Supplementary Figure
1C).
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We found no evidence for a difference in hazard ratios of CRC for biallelic mutation carriers
between males and females (108 (95%CI, 25.9–454) vs 129 (95%CI, 43.7–380); p=0.85),
nor for monoallelic mutation carriers between males and females (2.46 (95%CI, 1.54–3.93)
vs 2.67 (95%CI, 1.67–4.26); p=0.81). Hazard ratio of CRC for Y179C monoallelic carriers
was higher than for G396D monoallelic carriers (4.81 (95%CI, 3.00–7.71) vs 2.42 (95%CI,
1.48–3.98); p=0.05), but there was no difference between biallelic carriers of Y179C and
G396D (p=0.84) (Supplementary Table 1).
The standard deviation of the polygenic component was estimated to be 1.11 (0.74–1.49,
p<0.001); see the Materials and Methods for a general formula relating this standard
deviation to the hazard ratio. At ages less than 50y this formula reduces to Pharoah’s
formula for early-onset disease7 and says that monoallelic MUTYH mutation carriers with an
affected first-degree relative have CRC incidences approximately 4.58 (for males) or 4.97
(for females) times the population incidences. However, Supplementary Figure 2 gives
precise hazard ratios for all ages and shows that by age 70y, Pharoah’s formula over-
estimates relative risks by roughly 30%.
DISCUSSION
Our finding of almost complete penetrance for biallelic MUTYH mutation carriers is
consistent with previous studies.8–10 There is some evidence that biallelic mutation carriers
move rapidly along a mutator phenotype progression to cancer.11 These findings support the
recommendation that biallelic mutation carriers should consider prophylactic total
colectomy with ileorectal anastomosis depending on the individual, age of presentation and
number and size of polyps present.12
We estimated monoallelic mutation carriers had on average, an approximately 2.5-fold
increased risk of CRC compared with the general population, consistent with one previous
study.13 This level of increased risk for monoallelic mutation carriers is similar to that for
people with a first-degree relative with CRC, who are recommended 5-yearly colonoscopy
starting 10y younger than the youngest case in the family and before age 50y.13 However,
monoallelic mutation carriers who have an affected first-degree relative were at
approximately 5-fold increased risk. For these carriers, colonoscopy beginning at age 40y,
with follow-up at intervals dependent on the presence or absence of polyps but no less often
than every 5 years, may be reasonable.
We observed strong evidence that CRC risks for carriers are highly heterogeneous. The
observed heterogeneity in risk could also be caused by environmental factors shared
between family members or by differences in risk between mutations. To our knowledge,
thus far the only study investigating modifiers of CRC risks for MUTYH mutation carriers
was on the relationship with hormone replacement therapy, which reported no evidence of
interaction between hormone replacement therapy and MUTYH mutations.3
In this study of 12 variants of MUTYH mutations, 93% of the MUTYH mutations were
Y179C and G396D (Supplementary Table 2); consistent with a previous study of
Caucasians.14 We found CRC risk was higher for monoallelic carriers of Y179C than for
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G396D; consistent with previous studies.3, 15 However, given our approach of genotyping
for 12 mutations by MS and WAVE followed by confirmatory Sanger sequencing of
MUTYH in carriers (Materials and Methods), there is the possibility that we missed other
pathogenic mutations in MUTYH that were not one of the 12 mutations genotyped. Although
we identified additional variants from Sanger sequencing, their pathogenicity was
considered inconclusive (unclassified variants) and therefore not included in this analysis.
Additional MUTYH mutations may reside in different ethnic groups however this cohort was
predominantly Caucasian.
We used sophisticated statistical techniques to adjust for ascertainment, to account for
residual familial aggregation of disease and therefore avoid bias, and to use data for all
family members, whether genotyped or not, and therefore maximized statistical power and
avoided survival bias.
In conclusion, using the largest international study to date we have produced unbiased
estimates of CRC risks for MUTYH mutation carriers which are the most precise and reliable
currently available. In addition to the confirmed very high risk of CRC to biallelic MUTYH
mutation carriers, CRC risk for monoallelic mutation carriers depends on family history and
can be sufficiently high to warrant consideration of more intensive CRC screening than for
the general population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Cumulative risk of colorectal cancer for (A) male and (B) female MUTYH mutation carriers.
Note that the risks for a monoallelic carrier with an affected firstdegree relative (FDR) who
is either untested, a noncarrier or a monoallelic carrier are virtually identical (see Table 1) so
the unbroken, darker grey lines cannot be distinguished in the figure.
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